Guardant Health, Inc.: Business Overview, Financials & Competitive Analysis
Guardant Health, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Guardant Health is a high-growth precision oncology leader benefiting from FDA approvals, expanding reimbursement, and strategic partnerships in liquid biopsy cancer detection. With a market capitalization of $13.6B and trailing twelve month revenue of $903M, Guardant Health demonstrates strong market position and rapid growth. In 2024, Guardant Health's revenue.
What is Guardant Health, Inc.'s industry? Guardant Health, Inc. (guardanthealth.com) operates in Precision Oncology & Liquid Biopsy Diagnostics. AskCyborg classifies Guardant Health, Inc. under Precision Oncology & Liquid Biopsy Diagnostics in its company registry.
Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FD...
Cyborg Score thesis
Guardant Health is a high-growth precision oncology leader benefiting from FDA approvals, expanding reimbursement, and strategic...
Read the full analyst-debate transcript →Get the Latest Guardant Health, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGuardant Health, Inc. Overview
Pro stress-test →Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research.
Strategic Profile
Pro stress-test →In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. The company is positioned at the intersection of precision oncology and diagnostic innovation, with recent strategic partnerships like the multi-year collaboration with Merck announced in January 2026. Clinical validation, regulatory wins, and operational efficiencies are improving reimbursement prospects and accelerating the company's path to profitability.
Competitive Landscape
Pro stress-test →Exact Sciences is one of Guardant Health's main competitors. The company operates in the precision oncology and liquid biopsy space alongside players like Natera and Illumina. Illumina and Guardant Health settled their dispute in 2023, signed a long-term supply agreement, and agreed to share specimen samples for cancer research.
Industry Context
Guardant Health, Inc. operates in Precision Oncology & Liquid Biopsy Diagnostics.
Key facts
Founded: 2012 · Headquarters: Palo Alto, US · Employees: ~1,400 · Revenue: $903M · Market cap: $13.6B